Lipids and atherosclerosis: Lessons learned from randomized controlled trials of lipid lowering and other relevant studies

Journal of Clinical Endocrinology and Metabolism

Volumn 87, Issue 2, 2002, Pages 423-437

  Kreisberg, Robert A ^a   Oberman, Albert ^b  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; C REACTIVE PROTEIN; CHOLESTEROL; FENOFIBRATE; FIBRINOLYTIC AGENT; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; CARBOXYLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID;

AGING; ANGIOCARDIOGRAPHY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DIET; DISEASE COURSE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ILEUM BYPASS; INFLAMMATION; ISCHEMIC HEART DISEASE; LIFESTYLE; LIPID OXIDATION; MORTALITY; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; STROKE; SUDDEN DEATH; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; BLOOD; CONTROLLED CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANGINA;

ACIDS, ACYCLIC; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; RANDOMIZED CONTROLLED TRIALS;

EID: 85047683015     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.87.2.8057     Document Type: Review

References (145)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival study (4S)
2. The Lipid Research Clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
7. Atherosclerosis: An inflammatory disease
8. Risk reduction
9. Treating ambulatory ischemia in coronary disease by manipulating the cell biology of atherosclerosis
10. Low-density lipoprotein-independent effects of statins
11. Pleiotropic effects of statins
12. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
13. Changes in sequential coronary arteriograms and subsequent coronary events
14. Modification of coronary artery disease progression by cholesterol-lowering therapy: The angiographic studies
15. Angiographic trials of lipid-lowering therapy
16. Effects of pravastatin in 3260 patients with unstable angina: Results from the LIPID study
17. The primary prevention of myocardial infarction
18. Prevalence and extent of atherosclerosis in adolescents and young adults
19. Association of coronary heart disease risk factors with microscopic qualities of coronary atherosclerosis in youth
20. Risk factors for coronary heart disease in men 18 to 39 years of age
21. Primary prevention of coronary heart disease: Guidance from Framingham
22. Applicability of cholesterol-lowering primary prevention trials to a general population: The Framingham heart study
23. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
24. Use of lipid lowering drugs for primary prevention of coronary heart disease: Meta-analysis of randomised trials
25. Statin trials and goals of cholesterol-lowering therapy
26. The aggressive low density lipoprotein lowering controversy
27. Benefits of reducing low density lipoprotein cholesterol concentrations to < 100 mg/dl
28. Current perspectives on statins
29. Improvement in endothelium-dependent brachial artery flow-mediated vasodilation with low-density lipoprotein cholesterol levels < 100 mg/dl
30. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
31. Cholesterol reduction yields clinical benefit: A new look at old data
32. Preventing coronary artery disease by lowering cholesterol levels: Fifty years from bench to bedside
33. Cholesterol-lowering therapy in secondary prevention: Remaining issues
34. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts
35. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial
36. The influence of diet on the appearance of new lesions in human coronary arteries
37. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
38. "The lower the better" in hypercholesterolemia therapy: A reliable clinical guideline?
39. On the relationship between cholesterol lowering and coronary disease event rate
40. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
41. Serum cholesterol and hemorrhagic stroke in the Honolulu heart program
42. Treatment of dyslipidemia. Room for improvement?
43. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks?
44. Nontraditional cardiovascular risk factors
45. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease. A working group report
46. Remnant lipoproteins as therapeutic targets
47. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
48. Report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
49. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
50. Helsinki Heart study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia
51. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy
52. Therapeutic approaches to reducing the LDL and HDL-associated risks of coronary heart disease
53. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial
54. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variable to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)
55. Effects of fluvastalin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations [Lipoprotein and Coronary Atherosclerosis Study (LCAS)]
56. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol
57. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
58. Niacin plus simvastatin, but not antioxidant vitamins, protect against atherosclerosis and clinical events in CAD patients with low HDLC
59. Hypertriglyceridemia and coronary heart disease
60. The epidemiology of triglyceride as a coronary artery disease risk factor
61. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial
62. Clinical lipidology at the end of the millennium
63. Small, dense low-density lipoprotein particles as a predictor for the risk of ischemic heart disease in men: Prospective results from the Quebec cardiovascular study
64. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women
65. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas Atherosclerosis Regression Study (STARS)
66. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford coronary risk intervention project
67. Lipoprotein (a) further increases the risk of coronary events in men with high global cardiovascular risk
68. Lipoprotein (a) and coronary heart disease: Meta-analysis of prospective studies
69. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
70. Conner memorial lecture. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology
71. Vulnerable plaque: Pathobiology and clinical implications
72. Healed plaque ruptures and sudden coronary death. Evidence that subclinical rupture has a role in plaque progression
73. Molecular bases of the acute coronary syndromes
74. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction
75. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
76. The effect of cholesterol-lowering and antioxidant therapy on endothellum-dependent coronary vasomotion
77. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study
78. The short term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction
79. Fluvastatin in acute myocardial infarction: Effects on early and late ischemia and events: The Florida trial
80. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial
81. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: A mechanism for reducing clinical events?
82. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies
83. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors
84. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subffaction profile, and low-density lipoprotein oxidizability
85. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL
86. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
87. Long-term effects of pravastatin on plasma concentration of C-reactive protein
88. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels
89. Effect of pravastatin on outcomes after cardiac transplantation
90. Statins as a newly recognized type of immumomodulator
91. Comparative study of HMG-CoA reductase inhibitors on fibrinogen
92. Effects of lipids and lipoproteins on thrombosis and rheology
93. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques
94. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells
95. Reductase inhibitor monotherapy and stroke prevention
96. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trials
97. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival study (4S)
98. Reduction of stroke incidence after myocardial infarction with pravastatin: The Cholesterol and Recurrent Events (CARE) study
99. Pravastatin therapy and the risk of stroke
100. Reduction of stroke events with pravastatin: The Prospective Pravastatin Pooling (PPP) Project
101. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: Results of the LIPID Atherosderosis substudy
102. Statins for stroke: The second story?
103. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The prospective pravastatin pooling project
104. Cholestero-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris
105. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: Results of the Cholesterol and Recurrent Events (CARE) trial
106. Risk factors for congestive heart failure in US men and women: NHANES I epidemiology follow-up study
107. Elderly patients at risk for coronary heart disease or stroke: Selecting an ideal product for lipid lowering
108. Lifetime risk of developing coronary heart disease
109. Sex differences in 2-year mortality after hospital discharge for myocardial infarction
110. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol and Recurrent Events (CARE) trial
111. Cardiovascular disease and dyslipidemia in women
112. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women: A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy
113. No effect of long-term hormone replacement on brachial flow-mediated vasodilation in the Estrogen Replacement and Atherosclerosis (ERA) trial
114. Design of the women's health initiative clinical trial and observational study
115. Estrogens, lipids and cardiovascular disease: No easy answers
116. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analysis of the Scandinavian Simvastatin Survival study
117. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial
118. Status report of lipid-lowering trials in diabetes
119. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The diabetes atherosclerosis intervention study, a randomised study
120. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
121. Management of dyslipidemia in adults with diabetes
122. UK prospective diabetes study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex
123. Cholesterol reduction and non-illness mortality: Meta-analysis of randomised clinical trials
124. Lack of relations of hostility, negative affect, and high-risk behavior with low plasma lipid levels in the coronary artery risk development in young adults study
125. Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin
126. Statins and the risk of dementia
127. Serum cholesterol level and mortality findings for men screened in the multiple risk factor intervention trial
128. Low serum cholesterol and haemorrhagic stroke in men: Korea Medical Insurance Corporatior study
129. Defining patient risks from expanded preventive therapies
130. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia
131. Long-term safety of hepatic hydroxymethyl glutary, coenzyme A reductase inhibitors
132. Primary and secondary prevention trials
133. Diet and coronary heart disease: Clinical trials
134. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and Reinfarction Trial (DART)
135. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon diet heart study
136. Lyon diet heart study. Benefits of a Mediterranean-style, national cholesterol education program/American heart association step I dietary pattern on cardiovascular disease
137. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI prevenzione trial
138. Vitamin E supplementation and cardiovascular events in high-risk patients
139. Is there a potential therapeutic role for vitamin E or other antioxidants in atherosclerosis?
140. Heart attacks: Gone with the century?
141. Management of type 2 diabetes mellitus and cardiovascular risk: Lessons from intervention trials
142. Beyond cholesterol lowering: Depicting the benefits of dietary intervention on cardiovascular disease